Ascletis Pharma's ASC10 IND application for COVID-19 receives Chinese regulatory approval.

M2 EQUITYBITES-August 4, 2022-Ascletis Pharma's ASC10 IND application for COVID-19 receives Chinese regulatory approval

(C)2022 M2 COMMUNICATIONS http://www.m2.com

China-based Ascletis Pharma Inc. (HKEX: 1672) announced on Wednesday that China National Medical Products Administration (NMPA) has accepted the company's Investigational New Drug (IND) application for ASC10, an oral inhibitor drug candidate targeting RNA-dependent RNA polymerase (RdRp) for COVID-19.

ASC10 is an orally bioavailable double prodrug that has a new...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT